Hypoglycemia
Board exam relevance: in 2 of more than 100 exam reports · rank 142- Synonyms
- low blood sugar, hypo, Whipple's triad, prolonged fast, hypoglycemia unawareness
- Specialty
- Internal medicine · Endocrinology & diabetes
- Last updated
- 10/2026 · Dr. Pascal Bafteh
Contents
Definition
Hypoglycemia is a low plasma glucose level that can trigger activation of the sympathetic nervous system and dysfunction of the central nervous system. In people with diabetes taking glucose-lowering drugs, a value < 70 mg/dl (< 3.9 mmol/l) is regarded as hypoglycemia.
Without diabetes, hypoglycemia is rare. To diagnose a hypoglycemic disorder, Whipple's triad has to be established: symptoms of hypoglycemia, a simultaneously low plasma glucose (< 55 mg/dl or < 3.0 mmol/l) and relief of symptoms after intake of glucose.
Classification
Severity levels in diabetes:
- Level 1: glucose < 70 mg/dl (< 3.9 mmol/l) but ≥ 54 mg/dl (≥ 3.0 mmol/l)
- Level 2: glucose < 54 mg/dl (< 3.0 mmol/l)
- Level 3 (severe): hypoglycemia in which assistance from another person is needed because of altered mental or physical status
Without diabetes, a distinction is made by timing (fasting or postprandial, about 1–3 hours after a meal) and by mechanism: with or without inappropriate insulin secretion.
Aetiopathogenesis
Causes
- In diabetes: glucose-lowering drugs are by far the most common cause. Physical exertion can also trigger hypoglycemia, particularly in type 1 diabetes.
- Without diabetes, with inappropriate insulin secretion: insulinoma; post-bariatric hypoglycemia (usually postprandial, histologically nesidioblastosis); non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS); autoimmune hypoglycemia (Hirata syndrome) caused by antibodies, usually in patients with other autoimmune diseases; surreptitious intake of glucose-lowering drugs (factitious hypoglycemia).
- Without diabetes, without inappropriate insulin secretion: alcohol and certain drugs, severe liver, kidney or heart failure, sepsis, malnutrition, adrenal insufficiency and inborn errors of metabolism such as glycogen storage diseases.
- Non-islet cell tumor hypoglycemia (NICTH): a tumor produces large amounts of aberrant forms of insulin-like growth factor 2 (IGF-2), which cause the hypoglycemia; by then the tumor is usually advanced.
- Pseudohypoglycemia: falsely low values caused by glucose consumption by blood cells when sample processing is delayed (especially in leukemia or polycythemia) or by poor perfusion of the fingers.
Clinical features
- Autonomic (adrenergic) symptoms: sweating, tremor, palpitations, restlessness and anxiety, feeling of warmth, nausea, hunger, paresthesias. Under controlled conditions they begin at about 60 mg/dl (3.3 mmol/l).
- Neuroglycopenic symptoms: headache, blurred or double vision, confusion, agitation, seizures, coma; usually from about 50 mg/dl (2.8 mmol/l).
- Older people: stroke-like presentations with aphasia or hemiparesis; hypoglycemia predisposes to stroke, myocardial infarction and sudden cardiac death.
- Impaired awareness of hypoglycemia: in type 1 diabetes, long-standing type 2 diabetes or frequent hypoglycemia the warning symptoms are absent, so severe episodes occur without prodromes.
- Counter-regulatory hyperglycemia: after an episode, glucose may rise markedly because of counter-regulation.
The thresholds vary between individuals: some people have no symptoms at these values, while others have typical complaints with normal glucose.
Diagnosis
- Glucose measurement: during symptoms, laboratory glucose from a tube that stops glycolysis (e.g. a fluoride tube). Home glucose meters and glucose sensors are inaccurate in the hypoglycemic range; HbA1c is not helpful.
- Work-up without an obvious cause: the same sample taken during hypoglycemia is used for insulin secretion markers (the circulating hormone, C-peptide and proinsulin), together with beta-hydroxybutyrate, screening for oral antidiabetic agents and IAA (autoantibodies against the hormone). This distinguishes hypoglycemia with inappropriate insulin secretion, hypoglycemia without it and factitious hypoglycemia.
- Prolonged fast: the standard is a supervised fast of up to 72 hours; in almost all patients 48 hours are sufficient. Glucose is measured every 4–6 hours and every 1–2 hours once it is below 70 mg/dl (3.9 mmol/l). If glucose falls below 55 mg/dl (3.05 mmol/l), the hormone parameters are drawn. The test ends after 72 hours or when glucose is ≤ 45 mg/dl (≤ 2.5 mmol/l) with symptoms.
- Postprandial symptoms: instead of a fast, a mixed test meal is used; glucose and the secretion markers are measured every 30 minutes for up to 4 hours.
Treatment principles
- Conscious patients receive rapidly absorbed oral carbohydrates, with a recheck after a short interval and repetition if needed, followed by complex carbohydrates.
- In impaired consciousness, glucose is given intravenously; without venous access, a counter-regulatory hormone is available for injection or nasal administration.
- After sulfonylureas or long-acting insulin, prolonged monitoring is required, followed by review of the cause, the treatment regimen and patient education.
Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.
Keep learning in the app
Further reading (open access)
Cross-references
Keep learning
Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.
Related pages: Type 2 diabetes mellitus · Primary aldosteronism (Conn's syndrome) · Hyperthyroidism
Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.